Skip to content

Category: Biotechnology

BlinkLab Receives $822,205 R&D Tax Incentive Refund Relating to Autism Diagnostic Tool Pilot Study and Clinical Research Initiatives

By API User

8 January 2026 — Perth, Australia | BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) has announced that it has received $822,205 under the Australian Government’s Research and Development (R&D) Tax Incentive program. The refund relates to eligible R&D expenditure incurred in connection with BlinkLab’s U.S. pilot study and its clinical research initiatives conducted in Australia, including … Continued

Portable biosensor may enable on-site PFAS detection

By API User

A portable biosensor developed at La Trobe University may allow rapid, on-site detection of toxic “forever chemicals” in water, removing the need for samples to be sent to specialist laboratories. The device is designed to detect per- and polyfluoroalkyl substances (PFAS), a group of more than 15,000 synthetic chemicals used in products such as firefighting foams, food packaging and stain-resistant fabrics. PFAS … Continued

4DMedical: UC San Diego Health adopts CT:VQ(TM)

By API User

Highlights• UC San Diego Health, consistently ranked in the top 10 in the U.S. for Pulmonology & Lung Surgery, commences clinical use of CT:VQ™ • UC San Diego Health becomes the fourth U.S. academic medical center to adopt CT:VQ™, following Stanford, University of Miami and Cleveland Clinic • Four academic medical center deployments achieved within … Continued

Nexsen advances U.S. market entry with FDA engagement for GBS rapid sensor whilst strengthening leadership team

By API User

6 January 2026 – Sydney, Australia | Nexsen Limited (ASX:NXN) has announced the commencement of formal engagement with the United States Food and Drug Administration (FDA) as it advances its rapid Group B Streptococcus (GBS) point-of-care diagnostic toward market entry into the world’s largest maternal health market. The Company has lodged a Pre-Submission with the … Continued

Memphasys Secures Long-Term European Supply Agreement Valued at a Minimum of ~A$925,000 – Initial Order Received

By API User

HIGHLIGHTS Five-year European supply agreement executed with Centro Fertilita Assistita (CFA Italia), one of Italy’s largest private IVF groups based in Naples, Italy.  Minimum purchase commitments of 3,000 cartridges in the first 24 months, followed by 1,500 cartridges annually thereafter. Minimum contract value of €525,000 (~A$925,000), based on 7,500 contracted cartridges at €70 per cartridge.  … Continued

INOVIQ’s CAR-EXOSOMES DELIVER POSITIVE IN VIVO EFFICACY AND SAFETY RESULTS IN BREAST CANCER

By API User

Key Facts: ·         Superior Tumour Inhibition – INOVIQ’s CAR-NK-EV therapeutic candidate achieved 61.5% tumour reduction over 28 days, outperforming unmodified NK-EVs ·         100% Survival – All mice treated with CAR-NK-EVs survived the study period, compared to 66.7% for controls ·         Excellent Safety Profile – CAR-NK-EV treatment was well tolerated, with no observable adverse effects ·         … Continued

4DMedical secures $30.2 million with options underwrite

By API User

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options • Additional funding results in a pro forma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a … Continued

First implant in the Totally Leadless CRT (TLC-AU) Study

By API User

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR … Continued

First OncoSil treatment in United Kingdom

By API User

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on … Continued

TGA Provides Regulatory Clearance for LTR Pharma’s SPONTAN® Phase II Clinical Study

By API User

10 December 2025 – Brisbane, Australia | LTR Pharma Limited (ASX:LTP) has today announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) to commence its clinical trial activities for a Phase II clinical study for its nasal erectile dysfunction treatment SPONTAN®. This follows confirmation and acceptance of the Company’s Clinical Trial Notification … Continued